CF-301 is the first bacteriophage-derived lysin to enter clinical development in the US. The clinical development program will investigate CF-301, in combination with approved anti-staphylococcal agents, for the treatment of Staph aureus bloodstream infections, including endocarditis, caused by methicillin-susceptible and methicillin-resistant bacteria.
A Phase 1 trial of CF-301 in healthy volunteers was concluded in December, 2015. No clinical adverse safety signals were observed. This study was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single escalating doses of CF-301 administered intravenously to healthy volunteers. Data from this study will be used to aid the design of future clinical trials.